Edition:
India

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

90.24USD
1:30am IST
Change (% chg)

$3.07 (+3.52%)
Prev Close
$87.17
Open
$87.54
Day's High
$90.37
Day's Low
$86.87
Volume
70,433
Avg. Vol
75,899
52-wk High
$104.34
52-wk Low
$47.50

Summary

Name Age Since Current Position

J. Warren Huff

65 2015 Chairman of the Board, President, Chief Executive Officer

Jason Wilson

49 2018 Chief Financial Officer, Executive Vice President, Strategy

Dawn Bir

48 2018 Executive Vice President, Chief Commercial Officer

Colin Meyer

40 2018 Chief Medical Officer and Executive Vice President, Product Development

Michael Wortley

71 2018 Executive Vice President, Chief Legal Officer

James Bass

60 2004 Independent Director

William McClellan

59 2017 Independent Director

R. Kent McGaughy

47 2004 Independent Director

Jack Nielsen

55 2006 Independent Director

William Rose

50 2016 Independent Director

Vineet Jindal

2017 Vice President, Strategy & Analytics

Biographies

Name Description

J. Warren Huff

Mr. J. Warren Huff is Chairman of the Board, President, Chief Executive Officer of Reata Pharmaceuticals Inc. Prior to founding Reata, Mr. Huff served as CEO in a number of biotechnology and information technology start-up enterprises. Mr. Huff started his career as an attorney with Johnson & Gibbs, P.C., where he was a partner and Chairman of the Corporate Securities Practice. Mr. Huff received a B.B.A. magna cum laude from the University of Texas at Austin and a J.D. from Southern Methodist University. Our Board believes that Mr. Huff is qualified to serve on our Board due to his extensive experience investing and working in the pharmaceuticals industry.

Jason Wilson

Mr. Jason Dauglas Wilson is the Chief Financial Officer, Executive Vice President, Strategy of Reata Pharmaceuticals Inc. Prior to joining Reata, he held positions as Vice President, Finance & Corporate Controller at Caris Diagnostics and as a Senior Manager in the health-sciences group at Ernst & Young LLP. He currently serves on the board of directors of CytoSen Therapeutics, a private company. Mr. Wilson holds a B.B.A. in Accounting from Henderson University and an M.B.A. from University of Central Arkansas.

Dawn Bir

Ms. Dawn C. Bir is the Executive Vice President, Chief Commercial Officer of Reata Pharmaceuticals Inc. Prior to joining Reata, Ms. Bir most recently served as Vice President of Sales with Pharmacyclics, LLC. From February 2013 to September 2016, she built and led their first hematology national sales organization of sales representatives, division managers and regional sales directors, responsible for the launch of IMBRUVICA® in the US and Puerto Rico. From October 2011 to February 2013, Ms. Bir served as Vice President Sales & Marketing with McKesson US Pharmaceutical, SKY Pharmaceuticals and RxPak. Prior thereto, she held positions of increasing responsibility within McKesson Corporation, Genentech, Inc. and Bristol-Myers Squibb Company. She currently serves on the board of directors of Geron Corporation, a publicly-traded company. Ms. Bir holds a B.S. in Biology from Binghamton University.

Colin Meyer

Mr. Colin John Meyer M.D. is Chief Medical Officer and Executive Vice President, Product Development of Reata Pharmaceuticals Inc. Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.

Michael Wortley

Mr. Michael D. Wortley is the Executive Vice President, Chief Legal Officer of Reata Pharmaceuticals Inc. Prior to joining Reata, Prior to joining Reata, Mr. Wortley was an attorney at Vinson & Elkins LLP from 1995 to March 2015, serving in various capacities, including Chief Operating Partner of the firm and Managing Partner of the Dallas office, and, prior to 1995, at Johnson & Wortley, P.C., serving as Chairman of the Board and President. He currently serves on the board of directors of Pioneer Natural Resources Company. Mr. Wortley earned a B.A. in Political Science from Southern Methodist University, a Master’s degree in Regional Planning from the University of North Carolina at Chapel Hill and a J.D. from Southern Methodist University Dedman School of Law.

James Bass

Mr. James Edward Bass is an Independent Director of Reata Pharmaceuticals Inc. Mr. Bass has been managing family assets and investments as his primary business activity. Mr. Bass is a member of the board of Snowbird Holdings, LLC and Trinity Summits, LLC. He previously served as an executive director of FB Gemini Limited, an Asian regional investment bank based in Hong Kong, prior to which he was an associate attorney and later a partner at Gibson, Dunn & Crutcher LLP. Mr. Bass graduated with a B.A. from Yale University and obtained his J.D. from Stanford University. Our Board believes that Mr. Bass is qualified to serve on our Board due to his extensive experience investing and extensive service on the boards of directors and boards of managers of other enterprises.

William McClellan

Mr. William D. McClellan, Jr., CPA., is an independent Director of Reata Pharmaceuticals Inc. Mr. McClellan, Jr. has served as the Chief Financial Officer of Aerin Medical Inc. since January 2018. Mr. McClellan, Jr. is a financial management consultant to healthcare and life sciences companies, serving as the managing member of Goodwater Consulting, LLC since March 2017. From June 2004 until June 2016, Mr. McClellan, Jr. was the Chief Financial Officer and Executive Vice President, Finance at On-X Life Technologies Holdings, Inc. Prior to June 2004, Mr. McClellan, Jr. held financial and accounting positions at various healthcare and other companies and was a certified public accountant serving as an auditor with PricewaterhouseCoopers for nine years. He currently serves on the board of directors of Apollo Endosurgery, Inc., a publicly-traded company, and chairs its audit committee. Mr. McClellan, Jr. received a B.B.A. in accounting from Abilene Christian University and is a certified public accountant. Our Board believes that Mr. McClellan, Jr. is qualified to serve on our Board due to his extensive experience in finance and accounting roles in the healthcare and life sciences industry and in serving as a certified public accountant at a large public accounting firm.

R. Kent McGaughy

Mr. R. Kent McGaughy, Jr. is an Independent Director of Reata Pharmaceuticals Inc. Prior to joining CPMG’s predecessor, Cardinal Investment Company, Inc., in 1997, he worked in mergers and acquisitions at Simmons & Company International. He currently serves on the boards of Apollo Endosurgery, Inc., a publicly-traded company, and several private companies. Mr. McGaughy, Jr. received his B.A. from The University of Texas (summa cum laude and member of Phi Beta Kappa) and his M.B.A. from Harvard Business School. Our Board believes that Mr. McGaughy, Jr. is qualified to serve on our Board due to his extensive experience investing and extensive service on the boards of directors of other companies.

Jack Nielsen

Mr. Jack B. Nielsen is an Independent Director of Reata Pharmaceuticals Inc. Mr. Nielsen is a Managing Director in Vivo Capital, LLC, a healthcare focused investment firm. Prior to March 1, 2017, Mr. Nielsen worked within the Novo A/S organization and its venture activities since 2001 in several roles, most recently being employed as a Senior Partner based in Copenhagen, Denmark. From 2006 to 2012, Mr. Nielsen was employed as a Partner at Novo Ventures (US) Inc. in San Francisco, where he established the office which provides certain consultancy services to Novo A/S. He currently serves on the board of directors of Crinetics Pharmaceuticals, Inc., a publicly-traded company. Mr. Nielsen in the past has served on the board of directors of Akebia Therapeutics, Inc., Merus, N.V. and Apollo Endosurgery, Inc., each of which is a publicly-traded company. He is also currently a member of the board of directors of a number of private companies. Mr. Nielsen received a M.Sc. in Chemical Engineering from the Technical University of Denmark, and a Masters in Management of Technology from Center for Technology, Economics and Management, Technical University of Denmark. Our Board believes that Mr. Nielsen is qualified to serve on our Board due to his extensive industry experience, his experience with venture capital investments and his board service for several companies in the biotechnology sector.

William Rose

Mr. William E. Rose is an Independent Director of Reata Pharmaceuticals Inc. Prior to Montrose, Mr. Rose was associated with HBK Capital Management from 1991 until 2012, serving in various capacities, including Co-Chief Investment Officer. He currently serves on the Board of Greenhill School and is also a member of the Investment Committee for the Dallas Museum of Art. Mr. Rose received a B.A. in Political Science from Duke University in 1989. Our Board believes that Mr. Rose is qualified to serve on our Board due to his extensive experience investing, his experience with venture capital investments and his board service for other enterprises.

Vineet Jindal

Basic Compensation

Name Fiscal Year Total

J. Warren Huff

934,500

Jason Wilson

--

Dawn Bir

--

Colin Meyer

625,500

Michael Wortley

--

James Bass

267,918

William McClellan

292,934

R. Kent McGaughy

260,785

Jack Nielsen

298,933

William Rose

263,805

Vineet Jindal

--
As Of  31 Dec 2018